Liver Cancer

Confidently treat liver cancer with an ablative dose, while sparing organs at risk. Higher doses of radiation have been shown to drive favorable outcomes.

Liver cancer is the fifth most common type of cancer worldwide, with 841,080 new cases each year.1 And it’s the fourth leading cause of cancer death, with 781,631 patients succumbing to the disease annually.1

Today, MRIdian is changing the paradigm for liver cancer treatment.

  • MRIdian can deliver ablative doses to difficult-to-treat tumors, including liver tumors.2,3
  • Evidence has shown that ablative dose, 75-100 Gy biological effective doses (BED10), drive favorable outcomes.2,3,4
  • On-table adaptation enables clinicians to re-optimize and escalate dose to 75-100 Gy BED10 while maintaining normal organ dose contraints.2,3
  • Real-time tumor tracking and gating reduce dose to organs at risk.2,3

Scroll down to learn more about MRIdian treatment for liver cancer.

 

1Ferlay, J., et al. (2018). Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer. Retrieved August 30, 2019 from https://gco.iarc.fr/today.
2Rosenberg S. A. et al. (2018). A multi-institutional experience of MR-guided liver stereotactic body radiation therapy. Advances in Radiation Oncology, 4(1), 142-149.
3Witt JS, Rosenberg SA, Bassetti MF. MRI-guided adaptive radiotherapy for liver tumours: visualising the future. Lancet Oncol. 2020 Feb;21(2):e74-e82. doi: 10.1016/S1470-2045(20)30034-6. PMID: 32007208.
4Toesca DA, Osmundson EC, Eyben RV, et al. Central liver toxicity after SBRT: An expanded analysis and predictive nomogram. Radiother Oncol. 2017;122(1):130–136.

 

Important Safety Information

Indications for Use (IFU): The MRIdian Linac system, with magnetic resonance imaging capabilities, is intended to provide stereotactic radiosurgery and precision radiotherapy for lesions, tumors, and conditions anywhere in the body where radiation treatment is indicated. The MRIdian Linac System is not appropriate for all patients, including those who are not candidates for magnetic resonance imaging.

Important Safety Information (ISI): Radiation treatments may cause side effects that can vary depending on the part of the body being treated. The most frequent ones are typically temporary and may include, but are not limited to, irritation to the respiratory, digestive, urinary or reproductive systems; fatigue; nausea; skin irritation; and hair loss. In some patients, side effects can be severe. Treatment sessions may vary in complexity and duration.

Radiation treatment is not appropriate for all cancers. You should discuss the potential for side effects and their severity as well as the benefits of radiation and magnetic resonance imaging with your doctor to make sure radiation treatment is right for you.

Disclaimer: The opinions and clinical experiences presented herein are specific to the featured physicians and the featured patients and are for information purposes only. Nothing in this material is intended to provide specific medical advice or to take the place of written law or regulations. Results of treatment presented in the videos and information on this webpage are not indicative of typical or future results.

Discuss treatment options with your doctor, including the risks and benefits of the entire course of treatment specific to your individual needs. MRIdian Linac systems are only available at appropriately equipped facilities with specially trained physicians.

Only On MRIdian

James Good, MD, Clinical Director of SBRT, GenesisCare Oxford

Patient: 54-yo female; ER(+) HER2(-) primary breast tumor, previously Tx w/ lumpectomy and post-op RT; presented with 3 liver mets on FDG PET and MRI

Treatment Options: Surgery too risky, not able to get complete disease; standard radiation not an option

Challenge: Lesion location: Very susceptible to motion; requires complex setup w/ abdominal compression and fiducials; movement up to 2 cm would lead to large ITV and irradiating healthy tissue; conventional Linac would compromise PTV dose to meet OAR constraints; likely reduce overall dose to avoid exceeding mean liver tolerance

MRIdian: 35 Gy in 5 Fx, keeping OARs in tolerance; daily adaptation for ablative dose to tumor while keeping critical structures within tolerance; real-time automated beam gating with patient directed breath-hold allowed accurate dose delivery

Outcome: Able to deliver 50 Gy to three lesions. Three-month follow-up shows clear ablation zone and elimination of tumor

Case courtesy of Dr. Good –  GenesisCare Oxford. Results of this case study are not predictive of future results.

Only On MRIdian

“MRIdian may radically change pediatric radiotherapy indications.”
Enis Özyar, MD, Professor of Radiation Oncology, Acibadem Maslak Hospital

Patient: 15-mo with very rare pediatric metastatic liver tumor and huge celiac lymph node compressing biliary system

Treatment Options: RT not typically offered due to risk to anatomy—small structure size and motion; patient not a candidate for chemo

Challenge: Understanding efficacy and safety of shorter hypofractionation schemes is critical to improving pediatric palliative care.  In this pediatric case, we aimed to deliver treatment within a short period of time with minimal toxicity. Technically, it was not possible to ideally treat this mass with other radiotherapy systems as we needed fiducial markers and adaptive approach

MRIdian: 25 Gy in 5 Fx, every other day

Outcome: ~40% reduction in size over course of Tx making on-table adaptive re-planning essential; would have never known tumor was shrinking if treated with x-ray-guided system

Case courtesy of Prof. Ozyar – Acibadem Hospital Maslak. Results of this case study are not predictive of future results.

Key Study Summary

MRIdian In The News Related To Liver Cancer

MRI-Guided radiation therapy

Carbone Cancer Center, University of Wisconsin - Madison, WI - 2:27 minutes

MDs: Paul Harari, MD; Michael Bassetti, MD, PhD

Producer: UW Health

Liver cancer

  • MRI and radiation therapy are delivered at the same time
  • Gate the radiation to move with the tumor
  • Minimizes radiation risk to organs; diminishing the amount of normal tissue that gets exposed to radiation

February 13, 2015

Sorry, no News Articles found.

Scientific Presentations Related To Liver Cancer

MRI-Guided Liver Radiation: Seeing What You are Missing

Michael Bassetti, MD, PhD
Carbone Cancer Center, University of Wisconsin – Madison
ASTRO 2019

Dr. Bassetti has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Liver MRI-Guided Stereotactic Body Radiation Therapy (SBRT)

Lorraine Portelance, MD
Sylvester Comprehensive Cancer Center, University of Miami Health System
ASTRO 2019

Dr. Portelance has been compensated by ViewRay for her services in preparing and presenting this material for ViewRay’s further use and distribution.

ViewRay MRIdian Linac: The Miami Cancer Institute Clinical Experience

Michael Chuong, MD
Miami Cancer Institute, Baptist Health South Florida
ASTRO 2018

Dr. Chuong has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Prospective Experience with Real-Time Online Adaptive Radiotherapy for Abdominal and Pelvic Malignancies

Lauren Henke, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
ASTRO 2018

Dr. Henke has been compensated by ViewRay for her services in preparing and presenting this material for ViewRay’s further use and distribution.

Quantitative Radiomics of Daily 0.35T MR Images for Prediction of Tumor Response in Pancreas and Liver

John Chetley Ford, PhD
Sylvester Comprehensive Cancer Center, University of Miami Health System
ASTRO 2018

Dr. Ford has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Plan QA for Adaptive RT – UCLA Approach

Youming Yang, Ph.D.
UCLA Health, Jonsson Comprehensive Cancer Center – Los Angeles, CA
AAPM 2017

Dr. Yang has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.

Sorry, no videos found.

  Global Info

CUSTOMER LOGIN

Please log in to access the ViewRay Customer Portal. To request access, please click here. Request will be reviewed within 2 business days.

Existing Users Log In
   

This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties. Cookie Policy

Accept